A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated...
A big step forwards in the management of muscle invasive bladder cancer in which platinum cannot be used has been taken in the KEYNOTE-905...
A Chinese ADC and a western ADC slugged it out at the 2025 ESMO held in Berlin.
Tarlatamab, a bi-specific T-cell engager drug added to innitial immunochemotherapy brought encouraging initial survival outcomes in the...
John P. Crown MD MBA: ESMO 2025, Berlin: Adjuvant Ribociclib Brought Longer Freedom from Metastases for Patients with HR+/HER2- Early...
Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC...
resectable-gastric-and-ge-junction adenocarcinoma-radiation-therapy-no-help
Domenica Lorusso MD PhD: Initial therapy with Pembrolizumab added to chemoradiotherapy boosts survival in high-risk locally advanced cervix...
James Larkin FRCP, PhD talks about the big changes in survival prospects for patients with advanced and metastatic melanoma that have take...
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European...
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting
bart-neyns-md-phd-injectng-cells-into-cranial-cavity-for-recurrent-glioblastoma-long-survival